GlassScriptPhysician profile
Richard Henry Johnigan
NPI 1851328306
$3,619.60
in general payments reported to CMS, 2019-2025
23 companies · $908 in 2025
The $908 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $122 · 2021: $32.48 · 2022: $124 · 2023: $583 · 2024: $814 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $502.16 | 2019-2025 | |
| Aerin Medical INC. | $472.53 | 2019-2025 | |
| Medtronic, INC. | $364.15 | 2022-2025 | Propel |
| Intersect Ent, INC. | $287.50 | 2019 | |
| Acclarent, INC | $286.83 | 2019-2023 | Trudi Nav Cable, Relieva Spinplus, Acclarent Aera |
| Stryker Corporation | $240.39 | 2019 | |
| Neurent Medical Limited | $185.85 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Hologic Sales and Service, LLC | $169.07 | 2023-2024 | Coolseal Generator |
| Inspire Medical Systems, INC. | $160.81 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $155.16 | 2023-2025 | Nucala |
| Integra Lifesciences Corporation | $152.05 | 2024-2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Medtronic USA, INC. | $118.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $111.15 | 2024-2025 | Dupixent |
| Genzyme Corporation | $98.75 | 2024-2025 | |
| Olympus America INC. | $82.68 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $44.92 | 2025 | Tezspire |
| Smith+Nephew, INC. | $40.92 | 2023 | Stravix Pl |
| Hikma Pharmaceuticals USA | $37.27 | 2024-2025 | Ryaltris |
| Convatec INC. | $31.32 | 2025 | |
| Lilly USA, LLC | $20.86 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $20.06 | 2019 | |
| Amgen INC. | $19.17 | 2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $17.47 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Johnigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.